teclistamab,daratumumab,talquetamab
genmab,janssen
['mmsm']
aa4: tt showed neutropenia g3/4 :44%, anemia/thrombocytopenia:26%. nf reported in 9%, no discontinuation due to hematological toxicity #mmsm #myeloma #medtiwtter #usmirc #asco23 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter